Technical Analysis for GRI - GRI Bio, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.64 | -6.76% | -0.05 |
GRI closed down 6.76 percent on Wednesday, November 20, 2024, on 5 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -6.76% | |
Narrow Range Bar | Range Contraction | -6.76% | |
Stochastic Reached Oversold | Weakness | -6.76% | |
Wide Bands | Range Expansion | -6.76% | |
Down 3 Days in a Row | Weakness | -6.76% |
Alert | Time |
---|---|
Fell Below 50 DMA | about 17 hours ago |
50 DMA Support | about 19 hours ago |
Down 5% | about 21 hours ago |
60 Minute Opening Range Breakdown | about 22 hours ago |
Down 3% | about 22 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Autoimmunity Liver Disease Natural Killer Cell Lymphocytes T Cell Natural Killer T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Autoimmunity Liver Disease Natural Killer Cell Lymphocytes T Cell Natural Killer T Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 105.5691 |
52 Week Low | 0.3034 |
Average Volume | 5,285,692 |
200-Day Moving Average | 4.07 |
50-Day Moving Average | 0.63 |
20-Day Moving Average | 0.83 |
10-Day Moving Average | 0.81 |
Average True Range | 0.15 |
RSI (14) | 43.50 |
ADX | 34.21 |
+DI | 29.42 |
-DI | 20.21 |
Chandelier Exit (Long, 3 ATRs) | 0.89 |
Chandelier Exit (Short, 3 ATRs) | 1.04 |
Upper Bollinger Bands | 1.10 |
Lower Bollinger Band | 0.57 |
Percent B (%b) | 0.13 |
BandWidth | 63.18 |
MACD Line | 0.02 |
MACD Signal Line | 0.06 |
MACD Histogram | -0.0428 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.77 | ||||
Resistance 3 (R3) | 0.78 | 0.74 | 0.75 | ||
Resistance 2 (R2) | 0.74 | 0.71 | 0.74 | 0.74 | |
Resistance 1 (R1) | 0.69 | 0.69 | 0.67 | 0.68 | 0.73 |
Pivot Point | 0.66 | 0.66 | 0.65 | 0.65 | 0.66 |
Support 1 (S1) | 0.60 | 0.62 | 0.59 | 0.60 | 0.54 |
Support 2 (S2) | 0.57 | 0.60 | 0.56 | 0.54 | |
Support 3 (S3) | 0.52 | 0.57 | 0.53 | ||
Support 4 (S4) | 0.51 |